Dana dhuwit perusahaan: VolitionRx Ltd. (VNRX)

VolitionRx Limited (VNRX) is implementing the Nu.Q epigenetic system for affordable oncology screening. Cash and cash equivalents demonstrate the current liquidity reserve, where 0.00 marks a new level. However, slow adoption of the tests by insurance companies is hindering the payback period. Currently, the financial foundation is partially supported by sales of veterinary diagnostic systems while awaiting approval for human tests.
Rincian analitis lan laporan data perusahaan volition.com (VNRX)

This indicator measures the volume of liquid assets to assess the issuer's ability to cover operating expenses and debts without external support. The current value of 0.00 within the context of VolitionRx Limited (VNRX) epigenetic test development determines the margin of safety prior to regulatory approval; therefore, the cash balance trend directly indicates either the risk of a capital shortfall or the sustainability of the business model.